Our Clinical Trials
Select your nearest location above for the full list of local trials, or scroll though the latest studies below.
Research study investigating a new cholesterol medication on reducing cardiovascular events in individuals living with, or at risk of cardiovascular disease.
Research study investigating a new cholesterol medication on reducing cardiovascular events in individuals living with, or at risk of cardiovascular disease.
Phase 3 clinical trial that will assess the effects of LY3437943 in participants who are overweight or obese and have knee OA
Phase 3 clinical trial that will assess the effects of LY3437943 in participants who are overweight or obese and have knee OA
A Randomised, Double-Blind, Placebo-Controlled, Parallel-Arm Study to Evaluate the Efficacy, Safety and Tolerability of 150 mg Sublingual Cannabidiol in Adults with Mild-to-Moderate Pain.
A Randomised, Double-Blind, Placebo-Controlled, Parallel-Arm Study to Evaluate the Efficacy, Safety and Tolerability of 150 mg Sublingual Cannabidiol in Adults with Mild-to-Moderate Pain.
A Randomised, Double-Blind, Placebo-Controlled, Parallel-Arm Study to Evaluate the Efficacy, Safety and Tolerability of 150 mg Sublingual Cannabidiol in Adults with Mild-to-Moderate Pain.
A Randomised, Double-Blind, Placebo-Controlled, Parallel-Arm Study to Evaluate the Efficacy, Safety and Tolerability of 150 mg Sublingual Cannabidiol in Adults with Mild-to-Moderate Pain.
This study aims to evaluate the immunogenicity and safety of ChulaCov19 BNA159 Vaccine as a Booster Dose.
This study aims to evaluate the immunogenicity and safety of ChulaCov19 BNA159 Vaccine as a Booster Dose.
This study aims to see if experimental drug, Xanamem™ is 'is effective in treating cognitive and depressive symptoms for people that have ongoing depression with cognitive symptoms.
Paratus Clinical is proud to be a Society for Clinical Research Sites member. We actively participate in discussions and decisions that ultimately impact the industry at large. Being a part of the SCRS community gives us the opportunity to be heard and allows us to partake in industry training and events.
T: 1300 742 326
